Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRM-3379 in Male Participants With Fragile X Syndrome
NCT07209462Phase 2Recruiting
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Nov 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of DNS-3379 in Fragile X syndrome (FXS), sponsored by Mirum Pharmaceuticals, Inc.. Started Nov 2025; status: recruiting.
02
Drugs
DNS-3379
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT07209462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07209462.